Elan in deal with Scherer

 

ELAN Corporation and US company R.R Scherer have signed a licence agreement providing Elan with an exclusive licence in the US, Britain, Ireland and certain other countries to market a treatment for Parkinson's disease which uses Scherer's technology. Scherer has developed its own patented formulation of selegiline, a drug used to treat the disease, using its zydis technology.